文献速递妇科

跨性别及性别非二元人群使用睾酮行性别肯定子宫切除术时的子宫内膜发现

Endometrial findings among transgender and gender nonbinary people using testosterone at the time of gender-affirming hysterectomy.
PubMed 文献 · Fertil Steril · 2021-02-12

增殖期者平均比萎缩期者年轻5.6岁。

要点

  • 使用睾酮者子宫内膜可呈增殖期或萎缩期,闭经者亦如此。
  • 本组无子宫内膜增生或恶性肿瘤,11%发现子宫内膜息肉。
  • 增殖期子宫内膜者平均比萎缩期者年轻5.6岁。

核心结论

  • 使用性别肯定睾酮的人群可表现为增殖期或萎缩期子宫内膜,包括术前闭经者。
  • 需进一步研究以制定该人群子宫内膜增生或癌症筛查的循证指南。

研究设计与样本

  • 研究设置:学术医学中心和公共安全网医院。

主要发现

  • 中位年龄31岁(IQR 27-40),中位BMI 27 kg/m2(IQR 24-30)。
  • 6例(7%)有分娩史,60例(74%)闭经。
  • 9例(11%)发现子宫内膜息肉,无子宫内膜增生或恶性肿瘤病例。
  • 双变量分析中增殖期子宫内膜者平均比萎缩期者年轻5.6岁;多变量模型中无临床因素与增殖期vs萎缩期子宫内膜相关。

临床怎么用

  • 对使用性别肯定睾酮者,即使闭经,子宫内膜也可能呈增殖期,评估时不应仅凭闭经判断内膜状态。
  • 本组无子宫内膜增生或恶性肿瘤,但样本量有限,筛查策略需个体化并等待进一步证据。

局限性

  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe clinical characteristics and associated endometrial findings of transgender and gender nonbinary people using gender-affirming testosterone. DESIGN: Retrospective case series. SETTING: Academic medical center and public safety net hospital. PATIENT(S): Eighty-one patients using gender-affirming testosterone therapy undergoing hysterectomy for the indication of gender affirmation from 2000 to 2018. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Preoperative clinical characteristics and endometrium surgical pathology diagnoses. RESULT(S): Median age was 31 years (interquartile range [IQR] 27-40), and median body mass index 27 kg/m2 (IQR 24-30). Six patients (7%) were parous and 60 (74%) had amenorrhea. Thirty-three patients (40%) had proliferative and 40 (50%) atrophic endometrium. Endometrial polyps were found in nine patients (11%) of the sample. Endometrial findings were similar in the subgroup of 60 patients with preoperative amenorrhea. There were no cases of endometrial hyperplasia or malignancy. In bivariate analysis, those with proliferative endometrium were found to be, on average, 5.6 years younger than those with atrophic endometrium. There were no clinical factors associated with having proliferative versus atrophic endometrium in multivariable models. CONCLUSION(S): People using gender-affirming testosterone may have either proliferative or atrophic endometrium, including people who present with amenorrhea. Further study is needed to develop evidence-based guidelines for appropriate screening for endometrial hyperplasia or cancer in this population.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Hawkins M, Deutsch MB, Obedin-Maliver J, et al. Endometrial findings among transgender and gender nonbinary people using testosterone at the time of gender-affirming hysterectomy. Fertil Steril. 2021. PMID: 33583596. doi:10.1016/j.fertnstert.2020.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。